series-b
Stage
1
Investors
About
GenEdit develops non-immunogenic nanoparticle delivery technologies to enable precise and safe transport of genetic medicines, including CRISPR-based therapies, to target cells for treating autoimmune diseases and other conditions.
Explore GenEdit's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.